Lv3
264 积分 2022-07-20 加入
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
23天前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
23天前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
29天前
已完结
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
1个月前
已完结
Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody
1个月前
已完结
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
1个月前
已完结
HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis
1个月前
已完结
Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
1个月前
已完结
c‐erbB‐3 protein expression in human breast cancer: comparison with other tumour variables and survival
1个月前
已完结
Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer
1个月前
已完结
皖公网安备34019202002308
